Žáčková, Daniela http://orcid.org/0000-0001-9802-8148
Semerád, Lukáš
Faber, Edgar
Klamová, Hana
Stejskal, Lukáš
Bělohlávková, Petra
Karas, Michal
Cmunt, Eduard
Černá, Olga
Procházková, Jiřina
Čičátková, Petra
Kvetková, Anežka
Horňák, Tomáš http://orcid.org/0000-0002-7003-3372
Skoumalová, Ivana
Srbová, Dana
Šálek, Cyril http://orcid.org/0000-0002-0021-3247
Buffa, David
Voglová, Jaroslava
Jurček, Tomáš
Folta, Adam
Ježíšková, Ivana
Žižková, Hana
Machová Poláková, Kateřina
Papajík, Tomáš
Žák, Pavel
Jindra, Pavel http://orcid.org/0000-0002-8415-7069
Svobodník, Adam
Štěpánová, Radka
Mayer, Jiří http://orcid.org/0000-0003-0567-9887
Funding for this research was provided by:
Ministerstvo Zdravotnictví Ceské Republiky (NU22-03-00136, NU22-03-00136, NU22-03-00136, NU22-03-00136, NU22-03-00136, NU22-03-00136, NU22-03-00136, NU22-03-00136, NU22-03-00136, NU22-03-00136, NU22-03-00136, NU22-03-00136)
Ministry of Health of the Czech Republic – Conceptual Development of Research Organization
National budget through MAYS, LRI CZECRIN
Article History
Received: 30 November 2023
Revised: 28 February 2024
Accepted: 29 February 2024
First Online: 12 March 2024
Competing interests
: DŽ served as a member of advisory board for Novartis, served on a speaker’s bureau for Novartis, Pfizer and Angelini, served as a consultant for Novartis and Angelini, and received travel grants from Novartis, Pfizer, Angelini and Astra Zeneca. LSe received travel grant from Novartis and Angelini. EF served as a member of advisory board for Novartis and Zentiva, served on a speaker’s bureau for Novartis, Zentiva, and Angelini, participated in an expert opinion panel for Pearls Health Cyber, and received travel support from ELN Foundation and Altium International. PČ served as a consultant for Novartis and received travel support from Novartis and Angelini. TH served on a speaker’s bureau for Novartis, served as a consultant for Angelini, and received travel grant from Novartis. PJ served as a member of advisory board for Novartis, Astra Zeneca, Takeda, and Bristol-Myers Squibb, and received travel grants from Novartis, Astra Zeneca, and MSD. JM received research support from Novartis, Bristol-Myers Squibb, and Pfizer. Other authors declare no competing interests.
: The HALF study was approved by the Multicentric Ethical Committee. The Anti-HALF questionnaire was approved by the Ethical Committees of all participating institutions.
: All patients provided informed written consent with participation in the HALF trial or in the Anti-HALF questionnaire project.